Seeking alternative biological therapies: the future of targeted molecular treatment.

  title={Seeking alternative biological therapies: the future of targeted molecular treatment.},
  author={Jochen H. Lorch and Marshall Roy Posner and Lori J Wirth and Robert I. Haddad},
  journal={Oral oncology},
  volume={45 4-5},
In recent years targeted therapies have expanded treatment options for patients with squamous cell cancer of the head and neck (SCCHN) considerably and have led to clinically significant benefit. However, the multitude of new targeted drugs that have emerged and are in development also represent a challenge and many years of carefully conducted clinical studies will be needed to explore their full potential. This article summarizes the most important recent developments in the targeted… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 49 references

Spanish head and neck cancer group (TTCC)

  • R Hitt, A Irigoyen, J Nuñez, et al. Phase II study of combination cetuximab, weekly paclitaxel in patients with metastaticrecurrent sq head, neck SCCHN
  • Proc Am Soc Clin Oncol 2007;25. abstract #6012…
  • 2009
1 Excerpt

A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A southwest oncology group (SWOG) trial

  • SK Williamson, J Moon, CH Huang, P Guaglianone, GT Wolf, SG. Urba
  • Proc Am Soc Clin Oncol
  • 2007
1 Excerpt

Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum-based therapy – results of a randomized phase III (extreme) study

  • JB Vermorken, R Mesia, V Vega
  • Proc Am Soc Clin Oncol,
  • 2007
1 Excerpt

EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN)

  • MS Kies, MS Ghebremichael, TL Katz, RS Herbst, H Youssoufian, B. Burtness
  • Proc Am Soc Clin Oncol
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…